Dexmedetomidine and Renal Transplants

Completed

• Conditions: Renal Failure

• Registration Number: NCT02019121
• Lead Sponsor: University of California, Davis

Brief Summary

Investigators aim to retrospectively research patients undergoing renal transplants that received dexmedetomidine perioperatively to see if dexmedetomidine use protects renal function. Investigators hope to elucidate any association between renal transplant patients and perioperative dexmedetomidine administration, these include (but are not limited to) UOP, Cr/GFR, morbidity, mortality, in hospital complications and failure rate. Investigators will research both living and cadaveric renal transplants.

Detailed Description

Not available

Study Timeline

• Study Start: 2013-10
• Study First Submitted: 2013-11-05
• Study First Submitted QC: 2013-12-17
• Study First Posted: 2013-12-24
• Primary Completion: 2020-02
• Study Completion: 2020-02
• Status Verified: 2022-07
• Last Update Submitted: 2022-07-05
• Last Update Posted: 2022-07-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 797

Inclusion Criteria

Patients greater than or equal to 18 years old that underwent renal transplant at UC Davis Medical Center -

Exclusion Criteria

Patients that did not undergo renal transplants and patients less than 18 years old will be excluded from the study.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Cr/GFR improvement, postoperative mortality/morbidity (within 30 days) and overall complications	5 years

Secondary Outcome Measures

Name	Time	Method
Graft failure, length of hospital stay (LOS), length of ICU stay, re-admission rate, infections, pulmonary complications.	5 years

Trial Locations

Locations (1)

UC Davis Health System; 🇺🇸 Sacramento, California, United States